Tolerability of Bisoprolol on Domiciliary Spirometry in COPD by Jabbal, Sunny & Lipworth, Brian J.
                                                              
University of Dundee
Tolerability of Bisoprolol on Domiciliary Spirometry in COPD
Jabbal, Sunny; Lipworth, Brian J.
Published in:
Lung
DOI:
10.1007/s00408-017-0061-y
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Jabbal, S., & Lipworth, B. J. (2017). Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. Lung, 196(1),
11-14. https://doi.org/10.1007/s00408-017-0061-y
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Apr. 2019
Lung
 
Tolerability of bisoprolol on domiciliary spirometry in COPD
--Manuscript Draft--
 
Manuscript Number: LUNG-D-17-00293R1
Full Title: Tolerability of bisoprolol on domiciliary spirometry in COPD
Article Type: Brief Report
Keywords: COPD;  spirometry;  FEV1;  FEV6;  beta blocker
Corresponding Author: Brian Lipworth, MD
University of Dundee School of Medicine
Dundee, UNITED KINGDOM
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University of Dundee School of Medicine
Corresponding Author's Secondary
Institution:
First Author: Sunny Jabbal, MB ChB
First Author Secondary Information:
Order of Authors: Sunny Jabbal, MB ChB
Brian J Lipworth, MD
Order of Authors Secondary Information:
Funding Information:
Abstract: We investigated if serial domiciliary measures of spirometry were sensitive at detecting
subtle effects of beta-2 blockade associated with bisoprolol in (n=17) patients with
COPD.
After a two week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist
(LABA): beclometasone/formoterol 100/6µg, patients' started additional a long acting
muscarinic receptor antagonist: (LAMA) Tiotropium 18µg, with concomitant weekly
dose titration of bisoprolol: 1.25mg-2.5mg-5mg. After a further week of bisoprolol 5mg,
they were stepped back down to (ICS/LABA) for one week.
Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of
0.46. Compared to baseline am FEV1 of 1.38L (95% CI 1.14-1.61L), both
ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically
significant mean falls of 100ml (1.28L, 95% CI 1.03-1.53L), and 120ml respectively
(1.26L, 95% CI 1.01-1.51L); equalling and exceeding the MCID of 100ml respectively.
These changes were disconnected from symptoms, reliever use and oxygen
saturation.
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Abstract: 26 
We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle 27 
effects of beta-2 blockade associated with bisoprolol in (n=17) patients with COPD.  28 
After a two week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): 29 
beclometasone/formoterol 100/6µg, patients’ started additional a long acting muscarinic receptor 30 
antagonist: (LAMA) Tiotropium 18µg, with concomitant weekly dose titration of bisoprolol: 31 
1.25mg-2.5mg-5mg. After a further week of bisoprolol 5mg, they were stepped back down to 32 
(ICS/LABA) for one week.  33 
Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of 0.46. Compared 34 
to baseline am FEV1 of 1.38L (95% CI 1.14-1.61L), both ICS/LABA/LAMA and ICS/LABA in 35 
conjunction with bisoprolol showed statistically significant mean falls of 100ml (1.28L, 95% CI 36 
1.03-1.53L), and 120ml respectively (1.26L, 95% CI 1.01-1.51L); equalling and exceeding the 37 
MCID of 100ml respectively. These changes were disconnected from symptoms, reliever use and 38 
oxygen saturation. 39 
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Introduction: 53 
There is a reluctance to prescribe beta-blocker therapy to patients with COPD and cardiovascular 54 
disease, even with cardioselective drugs, due to concerns of potential bronchoconstriction (1, 2). 55 
Accumulating evidence however, suggests that more commonly used cardioselective agents  56 
such as bisoprolol do not negatively impact upon laboratory based  measures of  pulmonary 57 
function, such as the forced expiratory volume in 1 second (FEV1), in patients with COPD (3).  58 
Whether the pulmonary tolerability of beta-blockers is interdependent with concomitant inhaled 59 
therapy, however, is yet to be established. Therefore it is important to dissect out the relative 60 
contribution of long acting beta-2 agonist (LABA) with or without long acting muscarinic receptor 61 
antagonists (LAMA), in terms brochoprotection against a small degree of potential beta-2 receptor 62 
antagonism with bisoprolol.  63 
It would seem logical that a high affinity LABA, such as formoterol, would competitively displace 64 
a beta-1 selective beta-receptor antagonist such as bisoprolol, which exhibits weaker binding 65 
affinity for the beta-2 receptor (4). In vivo however, it has previously been demonstrated that 66 
bisoprolol even at a dose of 5mg significantly blunts the beta-2 mediated response to isoprenaline, 67 
albeit to a lesser than non-selective drugs (5). Moreover, as M3 muscarinic receptors are known 68 
to be involved in mediating bronchoconstriction with beta-blockers the addition of LAMA might be 69 
expected to confer additional protection in terms of pulmonary tolerability of bisoprolol in patients 70 
with COPD. In this regard non-selective beta blockers such as carvedilol are not used on a routine 71 
basis for patients with COPD. 72 
Furthermore, given that COPD is characterised by persistent symptoms and airflow limitation, a 73 
conventional spot measure of FEV1 done in a laboratory setting may not pick up more subtle 74 
adverse effects of bisoprolol as compared to serial domiciliary testing.  75 
 76 
Methods: 77 
A previous proof of concept study (6) (NCT01656005) prospectively studied patients aged 40-80 78 
years, with GOLD B and C stage COPD, who in brief  after a two week run in on inhaled 79 
corticosteroid (ICS) and LABA as beclometasone/formoterol  100/6µg (Fostair, Chiesi, 80 
Manchester , UK)  2 puffs bid , started concomitant weekly dose titration with bisoprolol (1.25mg-81 
2.5mg-5mg). They were then were placed on triple  inhaler therapy with  ICS/LABA/LAMA as 82 
Fostair with Tiotropium (Spiriva Handihaler, Boehringer Ingelheim, Bracknell ,UK) 18µg od for 1 83 
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week ,and then  stepped down again  to ICS/LABA (Fostair) for a further week. This study was 84 
approved by the East of Scotland Regional Ethics Committee (12/ES/0054), and completed at 85 
Ninewells Hospital, Dundee, UK. 86 
Here we report on unpublished data in a subgroup of 17 patients in which domiciliary 87 
measurements were available, comprising daily FEV1 and  forced expiratory volume in 6 seconds 88 
(FEV6), an acceptable surrogate for forced vital capacity in COPD  (7) ,measured with a Piko-6 89 
digital lung function meter (Nspire ,Hertford ,UK). Patients were issued paper diary cards during 90 
which they noted their daily global symptom score on a scale of 0-3. This represented their overall 91 
COPD symptoms that day and was rated from 0=none, 1=mild, 2=moderate, 3=severe. This 92 
allowed patients to consider their symptoms in context to their daily lives, activities and 93 
environment. Domiciliary resting heart rate and oxygen saturation were also measured, by a pulse 94 
oximeter (Merlin M-Pulse Lite, Merlin Medical, Rhymney, UK). The impact of bisoprolol 5mg OD 95 
was compared while receiving concomitant ICS/LABA/LAMA and ICS/LABA verses pre beta-96 
blocker baseline (while taking ICS/LABA).  97 
We analysed the last 4 days of values (which were time averaged) prior to taking bisoprolol 98 
(baseline) as well as while taking bisoprolol with either dual or triple inhaled therapy. These were 99 
then compared using repeated measures ANOVA with post hoc Bonferroni correction to obviate 100 
confounding the overall alpha error by multiple pairwise comparisons  (P<0.05 two tailed) . 101 
Results: 102 
80% of the patients were male, with a mean age of 64 years, mean FEV1 52% predicted, mean 103 
FEV1/FVC ratio of 0.46, mean 50 pack year smoking history, and 7% mean FEV1 reversibility to 104 
salbutamol 400µg. Results are presented in table 1. Compared to baseline, both ICS/LABA/LAMA 105 
and ICS/LABA in conjunction with bisoprolol were associated in similar mean falls in morning 106 
domiciliary FEV1, amounting to means of 100ml and 120ml respectively. There was no statistically 107 
significant difference between ICS/LABA/LAMA and ICS/LABA while taking bisoprolol for either 108 
FEV1 or FEV6. Despite bisoprolol producing a mean domiciliary heart reduction of 11 beats/min, 109 
there was no significant decline in oxygen saturation compared to baseline. Moreover the mean 110 
symptom score did not change while taking bisoprolol, remaining at a mild level. There was also 111 
no significant difference in reliever use with salbutamol pre or post beta blocker. We observed no 112 
significant correlation between either peripheral blood eosinophil count (mean 215 (95%CI 154-113 
275) cells/µl) or reversibility to salbutamol and percentage fall in domiciliary FEV1 or FEV6 whilst 114 
taking bisoprolol (figure).  115 
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Discussion 116 
Our results showed that the effect of bisoprolol on domiciliary morning FEV1 was not only 117 
statistically significant but also equalled (with ICS/LABA/LAMA) or exceeded (with ICS/LABA) the 118 
minimal clinically important difference value of 100ml (8) . We were surprised to find such an 119 
effect as we previously did not detect any significant impact on laboratory spot FEV1 120 
measurement with bisoprolol in conjunction with either dual (mean FEV1 fall of 10ml) or triple 121 
concomitant inhaler therapy (mean FEV1 increase of 30ml)  . This illustrates the superior 122 
sensitivity of measuring serial domiciliary lung function for detecting more subtle changes 123 
associated with bisoprolol in COPD.   However despite the reductions in FEV1 and corroborating 124 
reduction in resting heart rate (due to beta-1 blockade) , there was no associated change in either 125 
salbutamol use, symptom score or oxygen saturation. This in turn infers there is a disconnect 126 
between FEV1 and FEV6 from either symptoms or gas exchange. The corollary being that a small 127 
decline in lung function may have little real life impact on patients being prescribed beta blocker 128 
therapy. Alternatively another viewpoint may be that lowering resting heart rate resulted in 129 
patients experiencing less dyspnoea throughout the day. Our study demonstrated a reduction in 130 
resting heart rate from 80 bpm to 69 bpm after bisoprolol; COPD patients with heart rates <75 131 
bpm have a decreased cardiovascular mortality versus those with a heart rate ≥75 (9).  132 
Bisoprolol is highly selective with a 14:1 ratio for β1 to β2 receptor affinity (10). However it is well 133 
recognised that although there may be dose related airways related beta-2 blockade with 134 
cardioselective drugs ,it is still  considerably less than with non selective agents  (11). In terms of 135 
trying to identify the potential impact of an asthmatic component of COPD on beta-2 blockade 136 
with bisoprolol, we did not observe any relationship of FEV1 fall to blood eosinophils or salbutamol 137 
reversibility. 138 
The failure of concomitant tiotropium as inhaled triple therapy to confer protection against 139 
bronchoconstriction with bisoprolol was surprising. However we appreciate that we did not have 140 
a baseline value for comparison while taking ICS/LABA/LAMA to assess the relative 141 
bronchodilator impact of tiotropium in the absence of bisoprolol. Another limitation of this proof of 142 
concept study is the small sample size, and that there was no placebo arm to compare with 143 
bisoprolol but only a baseline value while taking ICS/LABA. Finally, our study duration was not 144 
sufficiently long enough to assess the impact of beta blocker therapy on exacerbations.  145 
In summary our  study demonstrates that in the context of single or dual long acting bronchodilator 146 
therapy , the beta-1 selective  antagonist  bisoprolol was associated with subtle but significant 147 
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falls in domiciliary FEV1 ,which were disconnected from  symptoms ,reliever use and oxygen 148 
saturation. Trials are now underway in COPD to evaluate the effects of bisoprolol on 149 
cardiopulmonary exercise testing (ClinicalTrials.gov NCT02380053) as well as to assess the 150 
impact on COPD exacerbations.  151 
 152 
 153 
 154 
 155 
Figure Legend: 156 
Correlation of percentage change in forced expiratory volume in one second (FEV1: top), and in 157 
six seconds (FEV6 bottom), and eosinophil counts. P=ns, no relationship observed.  158 
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Table 1. Results of domiciliary measures 
 
 
 
 BASELINE 
(OFF BISOPROLOL) 
ICS/LABA/LAMA 
(+BISOPROLOL) 
ICS/LABA 
(+BISOPROLOL) 
FEV1 AM (L) 1.38 (1.14- 1.61) 1.28 (1.03- 1.53)* 1.26 (1.01- 1.51)* 
FEV1 PM (L) 1.38 (1.12- 1.63) 1.32 (1.06- 1.57) 1.29 (1.04- 1.54)* 
FEV6 AM (L) 2.46 (2.06- 2.85) 2.33 (1.90-2.25) 2.27 (1.84-2.69) 
FEV6 PM (L) 2.50 (2.12-2.89) 2.39 (1.98- 2.80) 2.33 (1.92-2.74)* 
SYMPTOMS AM 0.27 (-0.21- 0.55) 0.28 (-0.48- 0.51) 0.34 (0.10- 0.57) 
SYMPTOMS PM 0.28 (-0.08- 0.57) 0.40 (0.16- 0.63) 0.47 (0.17-0.77) 
RELIEVER USE AM 0.6 (0.2- 1.3) 0.8 (0.2- 1.7) 1.0 (0.1- 2.0) 
RELIEVER USE PM 1.7 (0.2-3.3) 1.5 (0.2-2.8) 1.9 (0.4- 3.4) 
HEART RATE (BPM) 80 (74-85) 69 (64-73)* 69 (65-73)* 
SP02 (%) 96 (95-97) 95 (94-97) 96 (95-97) 
Domiciliary data are presented as means and 95% CI. *P<0.05 vs pre beta-blocker baseline while 
taking bisoprolol and concomitant ICS/LABA or ICS/LABA/LABA. Reliever use equates to puffs of 
salbutamol. No difference was observed between ICS/LABA/LAMA and ICS/LABA while taking 
bisoprolol. 
Table Click here to download Table Table 1.docx 
